Scientific research and technology has vastly increased our knowledge of bleeding disorders in the last few decades. But still, not everyone is treated successfully.
The development of long acting concentrates, by-pass therapy, gene therapy, modifications of activation and control of the clotting system has brought increasing knowledge of clotting factor immunogenicity so that we have the potential to meet the needs of every patient by 2030.
Erik Berntorp, Malmö Centre for Thrombosis and Haemostasis, is the principal investigator for several multinational studies and a reviewer of numerous scientific journals such as Blood, Journal of Thrombosis and Hemostasis and Hemophilia. He has published over 300 papers in peer-reviewed journals and has been the editor for a number of major textbooks including Textbook of Hemophilia and von Willebrand Disease – Basic and Clinical Aspects.
Berntorp will share his knowledge at the Medical Plenary Session on Tuesday from 09:30-10:00, room A4, during Hemophilia Treatment in 2030.